[{"NetIncomeLoss_3_FY_USD":-523083.0,"AssetsCurrent_0_FY_USD":1304791.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3_FY_USD":0.0,"StockIssuedDuringPeriodValueNewIssues_3_FY_USD":25000.0,"NetCashProvidedByUsedInInvestingActivities_3_FY_USD":-149500000.0,"AccruedLiabilitiesCurrent_0_FY_USD":388507.0,"CommitmentsAndContingencies_0_FY_USD":null,"GeneralAndAdministrativeExpense_3_FY_USD":576035.0,"PreferredStockSharesOutstanding_0_FY_shares":0.0,"ProceedsFromRelatedPartyDebt_3_FY_USD":136590.0,"GainLossOnInvestments_3_FY_USD":52952.0,"Liabilities_0_FY_USD":5621007.0,"Cash_0_FY_USD":1001032.0,"PaymentsOfStockIssuanceCosts_3_FY_USD":3375988.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_3_FY_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_FY_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_3_FY_USD":151050602.0,"ProceedsFromIssuanceOfPrivatePlacement_3_FY_USD":4990000.0,"AssetsHeldInTrustNoncurrent_0_FY_USD":149552952.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_FY_USD":0.0,"IncreaseDecreaseInPrepaidExpensesOther_3_FY_USD":303759.0,"TemporaryEquityCarryingAmountAttributableToParent_0_FY_USD":140236730.0,"RepaymentsOfRelatedPartyDebt_3_FY_USD":200000.0,"UnrecognizedTaxBenefits_0_FY_USD":0.0,"PreferredStockSharesIssued_0_FY_shares":0.0,"CashEquivalentsAtCarryingValue_0_FY_USD":1926.0,"AdditionalPaidInCapital_0_FY_USD":5522572.0,"RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_3_FY_USD":11717.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_3_FY_USD":8755181.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_FY_USD":1001032.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_FY_USD":1001032.0,"LiabilitiesCurrent_0_FY_USD":388507.0,"NetAssetValuePerShare_0_FY_USD":1.0,"IncreaseDecreaseInAccruedLiabilities_3_FY_USD":318507.0,"NetCashProvidedByUsedInOperatingActivities_3_FY_USD":-549570.0,"StockholdersEquity_0_FY_USD":5000006.0,"PreferredStockSharesAuthorized_0_FY_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_FY_USD":150857743.0,"PreferredStockValue_0_FY_USD":0.0,"ProceedsFromIssuanceInitialPublicOffering_3_FY_USD":149500000.0,"OperatingIncomeLoss_3_FY_USD":-576035.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_FY_USD":0.0,"PreferredStockParOrStatedValuePerShare_0_FY_USD":0.0001,"Assets_0_FY_USD":150857743.0,"RetainedEarningsAccumulatedDeficit_0_FY_USD":-523083.0,"PrepaidExpenseCurrent_0_FY_USD":303759.0,"Ticker":"NAUT","CIK":"1808805","name":"ARYA SCIENCES ACQUISITION CORP III","OfficialName":"Nautilus Biotechnolgy Inc. Common Stock","form":"10-K","period":"20201231","fy":"2020.0","fp":"FY","qtrs":"3","uom":"USD","footnote":"nan","Market Cap":"491482396.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210330"}]